Given prior evidence linking elevated HMGB1 to depression and stress-related neuroimmune dysregulation, it was hypothesized that ECT might exert therapeutic effects by downregulating HMGB1-mediated inflammatory pathways or modulating sRAGE expression. Here, HMGB1 is linked to depressive symptom measurement.